Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Romi Ghose"'
Neratinib causes non-recoverable gut injury and reduces intestinal cytochrome P450 3A enzyme in mice
Publikováno v:
Toxicol Res (Camb)
Neratinib is a pan-HER tyrosine kinase inhibitor newly approved by FDA in 2017 to treat HER2-positive breast cancer, but the phase III trial of neratinib showed that 96% of the patients taking neratinib experienced diarrhea. So far very few mechanist
Publikováno v:
Expert Rev Vaccines
OBJECTIVE: Infectious disease emergencies like the 2013-2016 Ebola epidemic and the 2009 influenza and current SARS-CoV-2 pandemics illustrate that vaccines are now given to diverse populations with preexisting pathologies requiring pharmacological m
Publikováno v:
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 166
Irinotecan is a first-line treatment for colorectal cancer and the prodrug of 7-ethyl-10-hydroxy-camptothecin (SN-38). However, its fatal gastrointestinal (GI) toxicity raises serious concern. In liver, irinotecan generates its inactive metabolite, S
Publikováno v:
Expert Opin Drug Metab Toxicol
Introduction Toxicity of chemotherapy drugs is the leading cause of poor therapeutic outcome in many cancer patients. Gastrointestinal (GI) toxicity and hepatotoxicity are among the most common side effects of current chemotherapies. Emerging studies
Publikováno v:
Current Opinion in Toxicology. :36-40
The importance of oxidative stress has been increasingly recognized in diabetes and related cardiovascular complications as well as in chemical-induced toxicity, which makes it a potential therapeutic target for tackling such health issues. On the ot
Publikováno v:
Chemico-biological interactions. 360
Irinotecan, a first-line chemotherapy for gastrointestinal (GI) cancers has been causing fatal toxicities like bloody diarrhea and steatohepatitis for years. Irinotecan goes through multiple-step drug metabolism after injection and one of its interme
Publikováno v:
Food and Chemical Toxicology. 171:113547
Autor:
Gabriel Tao, Romi Ghose
Publikováno v:
The FASEB Journal. 35
Publikováno v:
Drug Metabolism and Disposition. 46:397-404
Cytochrome P450 CYP3A4 is the most abundant drug-metabolizing enzyme and is responsible for the metabolism of ∼50% of clinically available drugs. Induction of CYP3A4 impacts the disposition of its substrates and leads to harmful clinical consequenc
Publikováno v:
Toxicology in Vitro. 41:75-82
The bacterial receptor, Toll-like receptor (TLR) 4 mediates inflammatory responses and have been linked to a broad array of diseases. TLR4 agonists are being explored as potential treatments for cancer and other diseases. We have previously shown tha